Date: 2011-12-16
Type of information: Services contract
Compound: development and supply of founder transgenic rabbits
Company: Pharming (The Netherlands) Renova Life (USA)
Therapeutic area: Hematological diseases - Genetic diseases - Rare diseases
Type agreement: services
Action mechanism:
Disease: hemophilia A
Details: Pharming Group has signed a service agreement with Renova Life, Inc, (RLI) a biotech company based in Maryland, USA. The agreement covers the development and supply of founder transgenic rabbits from RLI to Pharming. The founder rabbits will enable Pharming to start the commercial production breeding process. The first protein to be expressed in the rabbits will be recombinant human Factor VIII (rhFVIII) for the treatment of haemophilia A.
RLI recently announced the birth of rhFVIII transgenic rabbits through their Chinese subsidiary, Lannuo Biotechnologies (Wuxi, China) and have previously had successful functional expression of rhFVIII in mice. Pharming will leverage its proprietary and validated rabbit platform for the production of recombinant human proteins to develop rhFVIII.
Financial terms: Financial details were not disclosed.
Latest news:
